NCT00149981No Longer Available不适用
A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 试验地点
- 1
研究概览
简要总结
Facilitated access to everolimus until it is commercially available and reimbursable by appropriate parties
详细描述
This is a treatment protocol designed only to provide access to everolimus (RAD) for maintenance immunosuppression. The objectives are to facilitate the management of patients on maintenance immunosuppression therapy who are completing everolimus trials,
- To provide everolimus maintenance therapy through this access program and
- To collect and review safety data for up to 120 months or until the project has been discontinued whichever comes first.
- To collect and review safety data for up to 120 months or when Certican is commercially available in the given indication and reimbursed by appropriate payors or the project has been discontinued whichever comes first.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female recipients of solid organ transplants
- •Subject is currently enrolled in an everolimus (RAD) trial sponsored by Novartis
- •Currently on investigational drug everolimus (RAD) therapy
排除标准
- •Inability or unwillingness to comply with immunosuppressive regimen.
- •Pregnancy.
- •History of acute organ rejection within the last 3 months.
- •Other protocol-defined inclusion/exclusion criteria may apply.
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A facilitated access program to provide Everolimus (RAD) for maintenance for patients completing therapy in RAD trials in solid organ transplantation. - The umbrella protocolEUCTR2004-001473-25-BEovartis Pharmaceuticals Corporation1,000
进行中（未招募）
不适用
A facilitated access program to provide Everolimus (RAD) for maintenance for patients completing therapy in RAD trials in solid organ transplantation.Solid organ transplantationEUCTR2004-001473-25-GBovartis Pharma Services AG1,000
Approved For Marketing
不适用
An Expanded Access Program of Emicizumab in Participants With Hemophilia A With InhibitorsHemophilia ANCT03154437Genentech, Inc.
No Longer Available
不适用
Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without CataplexyNarcolepsy Without CataplexyNarcolepsy With CataplexyNCT03433131Harmony Biosciences, LLC
No Longer Available
不适用
Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401MelanomaNCT03593499Biogen